Validity of the Beck Depression Inventory-Fast Screen in multiple sclerosis

Introduction: The Beck Depression Inventory-Fast Screen (BDI-FS) is a brief self-report inventory designed to evaluate depression in patients with medical illness. A s depressive disorder is especially prominent in multiple sclerosis (MS), a cost-effective procedure for identifying depressive disord...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis 2003-08, Vol.9 (4), p.393-396
Main Authors: Benedict, R HB, Fishman, I, McClellan, M M, Bakshi, R, Weinstock-Guttman, B
Format: Article
Language:English
Subjects:
Adult
Biological and medical sciences
Depressive Disorder - complications
Depressive Disorder - diagnosis
Female
Humans
Male
Mass Screening
Medical sciences
Middle Aged
Multiple Sclerosis - complications
Multiple Sclerosis - psychology
Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
Neurology
Personality Inventory
Psychometrics
Reproducibility of Results
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: The Beck Depression Inventory-Fast Screen (BDI-FS) is a brief self-report inventory designed to evaluate depression in patients with medical illness. A s depressive disorder is especially prominent in multiple sclerosis (MS), a cost-effective procedure for identifying depressive disorder in MS is sorely needed. The BDI-FS may be useful in this regard although, to date, its validity in MS patients has not been assessed. Methods: Fifty-four consecutive MS patients were studied. A ll underwent psychological assessment, which included the BDI-FS and other self-report measures of depression. Forty-eight caregiver/informants were interviewed using the Neuorpsychiatric Inventory (NPI). Retrospective chart reviews were conducted by a single trained research assistant, blind to the results of psychological testing and interviews, to determine if antidepressant medications had been prescribed. Results: The BDI-FS was significantly correlated with other self-report measures of depression (P B-0.001) and with informant reported dysphoria (P B-0.01), In addition, BDI-FS scores discriminated MS patients undergoing treatment for depressive disorder from untreated MS patients (P =0.01). Conclusion: These data support the concurrent and discriminative validity of the BDI-FS in MS. A s the test is brief and not confounded with neurological symptoms, it is recommended for depression screening in this population.
ISSN:1352-4585
1477-0970
DOI:10.1191/1352458503ms902oa